Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
With
AstraZeneca
This post-marketing study will enroll approximately 5,200 subjects 2-17 years of age who are seeking care in an outpatient setting for febrile acute respiratory illness. This study will begin in the fall of 2013 and will be completed after 4 influenza seasons (i.e.after the 2016-2017 influenza season). No investigational product will be administered in this study. A nasal swab will be obtained and tested for the presence of influenza virus and other viral pathogens. This study will be conducted at 4 sites in the United States of America. The duration of study participation for each subject is one day.
Age
2–17
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Community-dwelling children and adolescents 2 to 17 years of age.
Written Informed Consent or Assent.
Acute respiratory illness documented at study visit or at home with fever (oral temperature ≥ 100.0° Fahrenheit at study visit, or history of fever reported by parents, or use of antipyretic prior to study visit)
Symptom onset less than 5 days prior to study visit.
Subject and/or subject's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator.
You may not be if
Treatment with an antiviral drug for influenza (oseltamivir or Tamiflu®, zanamivir or Relenza®) during the 14 days before enrollment
Any condition that, in the opinion of the investigator, would interfere with interpretation of subject safety or study results
Concurrent enrollment in another clinical study
Patient already enrolled during this influenza season
Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
